Pr ELIDEL ® (pimecrolimus) cream Now Reimbursed Under Alberta’s Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis

LAVAL, QC, July 28, 2026 - Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) announces that Pr ELIDEL ® (pimecrolimus) cream is now listed under Alberta’s public drug plan for eligible patients. ELIDEL ® cream is indicated for second-line therapy for short-term and intermittent long-term therapy of mild to moderate atopic dermatitis in non-immunocompromised patients 3 months of age and older, in whom the use of alternative, conventional therapies is deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or intolerant of alternative, conventional therapies. 1 ELIDEL ® has been available by prescription in Canada since 2003. The product is already reimbursed under several public drug plans across Canada, including those in British Columbia, Saskatchewan, Ontario, and Québec. With Alberta now adding coverage, more patients will have access to this treatment option. “We are delighted that public reimbursement in Alberta will enable more patients living with atopic dermatitis to access ELIDEL ® . Improving access to treatment is critical to helping patients better manage their medical condition, while supporting improved health outcomes,” said Amy Cairns, General Manager, Bausch Health, Canada Inc. “The reimbursement of ELIDEL ® in Alberta is fantastic news for patients living with atopic dermatitis,” said Dr. Jessica Asgarpour, MD, FRCPC, FAAD, DABD, dermatologist at the Skin Health and Wellness Centre in Calgary, Alberta . “Greater access to a topical non-corticosteroid treatment option will help physicians tailor therapy to individual patient needs and expand treatment choices for patients seeking alternatives to topical corticosteroids.” About Atopic Dermatitis Atopic dermatitis is a chronic, relapsing, and remitting inflammatory skin disease 2 commonly encountered by primary-care providers. 3 It affects all ages. In infants, onset occurs most often between 3 and 6 months. 2 In children and teenagers, the estimated prevalence is 10 to 15%. 3 About 40% of these continue to be affected as adults. 3 About 85% of all patients have mild to moderate disease. 3

The release as fetched from its publisher. bauschhealth.com ↗